U.S. FDA Considers Using Third-Party Inspectors to Enhance Global Reach
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA is talking about adding an outsourced inspectorate to help it police the globally outsourced pharmaceutical manufacturing industry
You may also be interested in...
User Fee Bill Puts Industry, U.S. FDA to Work On Global Supply Chain Risks
The user fee legislation U.S. Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains.
Is Silence Golden For Brand Companies On Inspection Fees?
The inspection and establishment fee issue likely will remain a prickly subject for brand companies in the coming years, especially if a program is successfully launched for generics.
FDA-EMA-TGA Joint Inspection Program To Be Permanent; Other Collaborations Expand
FDA, the European Medicines Agency and Australian Therapeutic Goods Administration intend to make permanent a pilot program allowing for joint facility inspections in what would be another step toward more U.S. reliance on foreign regulator and third-party data and a reduction in inspection burden.